Dosimetric comparison of brachyablation and stereotactic ablative body radiotherapy in the treatment of liver metastasis

BA leads to a higher target dose, similar dose to organs at risk, but potentially with lower target coverage compared with SABR. Further work is needed to determine ideal suitability for mono vs. combination therapy with this approach.